Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.59 |
| ▸ | MMP1 | P03956 | 10/20 | 0.55 |
| ▸ | FCER2 | P06734 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 12/20 | 0.49 |
| ▸ | MMP3 | P08254 | 6/20 | 0.49 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209529 | 1.00 | CAPN1 (0.59) | CAPN1MMP1FCER2MMP2MMP3 | |
| SCHEMBL8345250 | 0.88 | CAPN1 (0.72) | CAPN1 | |
| SCHEMBL7762773 | 0.88 | CAPN1 (0.72) | CAPN1 | |
| SCHEMBL7762765 | 0.88 | CAPN1 (0.72) | CAPN1 | |
| SCHEMBL7762727 | 0.86 | FCER2 (0.56) | CAPN1MMP1FCER2MMP8 | |
| SCHEMBL7762736 | 0.86 | FCER2 (0.56) | CAPN1MMP1FCER2MMP8 | |
| SCHEMBL8344939 | 0.86 | FCER2 (0.56) | CAPN1MMP1FCER2MMP8 | |
| SCHEMBL7202933 | 0.86 | CAPN1 (0.64) | CAPN1MMP1FCER2MMP2MMP3 | |
| SCHEMBL8349149 | 0.85 | L3MBTL1 (0.59) | CAPN1MMP2 | |
| SCHEMBL7206727 | 0.85 | L3MBTL1 (0.59) | CAPN1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |